Loading
RSPO2 (R-spondin-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer and Colorectal cancer.
Activator of the canonical Wnt signalling pathway by acting as a ligand for LGR4-6 receptors. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signalling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signalling pathway.
Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes literature 0.94, animal model 0.55, genetic association 0.62, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Colorectal Adenocarcinoma.
In plain words · RSPO2 (R-spondin-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer and Colorectal cancer.
RSPO2 (R-spondin-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Breast cancer and Colorectal cancer.
Activator of the canonical Wnt signalling pathway by acting as a ligand for LGR4-6 receptors.
No product in this corpus aims at RSPO2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 2003. Earliest sequence paper UniProt cites for the protein: Clark H.F. et al, Genome Res, 2003, "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment". Source.
Sources: HGNC HGNC:28583 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q6UXX9 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000147655 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: colorectal cancer 0.52, prostate cancer 0.58, breast cancer 0.57 (GraphQL API, CC0)); IntOGen RSPO2 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Activator of the canonical Wnt signalling pathway by acting as a ligand for LGR4-6 receptors. Upon binding to LGR4-6 (LGR4, LGR5 or LGR6), LGR4-6 associate with phosphorylated LRP6 and frizzled receptors that are activated by extracellular Wnt receptors, triggering the canonical Wnt signalling pathway to increase expression of target genes. Also regulates the canonical Wnt/beta-catenin-dependent pathway and non-canonical Wnt signalling by acting as an inhibitor of ZNRF3, an important regulator of the Wnt signalling pathway. During embryonic development, plays a crucial role in limb specification, amplifying the Wnt signalling pathway independently of LGR4-6 receptors, possibly by acting as a direct antagonistic ligand to RNF43 and ZNRF3, hence governing the number of limbs an embryo should form. Location: Secreted (UniProt). Locus 8q23.1 (HGNC).
Query for this target: (TITLE:"RSPO2" OR ABSTRACT:"RSPO2" OR TITLE:"R-spondin 2" OR ABSTRACT:"R-spondin 2" OR TITLE:"R-spondin-2" OR ABSTRACT:"R-spondin-2" OR TITLE:"MGC35555" OR ABSTRACT:"MGC35555") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RSPO2, not a curated reading list.
Shares Recurrent R-spondin fusions in colon cancer, Wnt / β-catenin, Gene fusion, Breast cancer (all types).
Shares Recurrent R-spondin fusions in colon cancer, Wnt / β-catenin, IntOGen, Breast cancer (all types).
Shares Wnt / β-catenin, IntOGen, Open Targets Platform, Colorectal cancer.
Shares Wnt / β-catenin, Open Targets Platform.
Shares Wnt / β-catenin, Colorectal cancer.
Shares Wnt / β-catenin, IntOGen, Open Targets Platform, Prostate cancer.
Shares Recurrent R-spondin fusions in colon cancer, Wnt / β-catenin, IntOGen, Open Targets Platform.
Shares Wnt / β-catenin, Colorectal cancer.